What is Cincor Pharma?
Cincor Pharma is a pharmaceutical company dedicated to developing targeted therapies for cardiovascular and metabolic disorders. Its core strategy revolves around innovative mechanisms of action, particularly focusing on aldosterone modulation. By selectively reducing aldosterone levels, Cincor Pharma aims to provide significant clinical benefits for patients suffering from hypertension and related conditions who may not respond adequately to conventional treatments. The company's lead therapeutic candidate is designed to address critical unmet medical needs in blood pressure management, targeting specific physiological pathways that contribute to sustained hypertension and cardiovascular complications. This approach holds the potential for broad applicability across diverse patient populations, reflecting a commitment to advancing personalized medicine in cardiovascular care.
How much funding has Cincor Pharma raised?
Cincor Pharma has raised a total of $386.6M across 3 funding rounds:
Series A
$50M
Series B
$143M
Stock Offering
$193.6M
Series A (2019): $50M with participation from 5AM Ventures and Sofinnova Investments
Series B (2021): $143M led by BVF Partners, venBio Partners, General Atlantic, and Adage Capital Management
Stock Issuance/Offering (2022): $193.6M, investors not publicly disclosed
Key Investors in Cincor Pharma
BVF Partners
BVF Partners is a private investment partnership specializing in fundamentally-driven public biotechnology investments, known for building concentrated, long-term stakes in small-cap biotech companies.
venBio Partners
venBio Partners is a life sciences investment firm that collaborates with industry leaders to develop innovative medicines and technologies, focusing on novel therapeutics for unmet medical needs.
General Atlantic
General Atlantic is a global growth equity firm providing capital and strategic support to high-growth companies across various sectors, including healthcare and life sciences.
What's next for Cincor Pharma?
The recent major strategic investment signifies a pivotal moment for Cincor Pharma, likely enabling the acceleration of its clinical development pipeline and the expansion of its research initiatives. This substantial backing, coupled with the company's focus on aldosterone modulation for cardiovascular and metabolic disorders, positions it for significant advancements. Future endeavors will likely involve progressing its lead therapeutic candidate through further clinical trials, potentially exploring new indications, and scaling its operational capacity to meet the demands of late-stage development and eventual commercialization. The company's strategic financing indicates a strong focus on achieving key milestones and solidifying its market position in the competitive biopharmaceutical landscape.
See full Cincor Pharma company page
